Key result
This article reviews the published data regarding biomarkers in the setting of mechanical circulatory support for advanced heart failure, highlighting areas of ongoing work and future interest.
This review summarizes current knowledge and future directions for the use of biomarkers in patients receiving mechanical circulatory support for advanced heart failure.
Answers are grounded in this paper and cite their sources.
Offers no practice change; leaves open biomarker utility in MCS pending prospective validation.
Heart failure is a complex multifaceted syndrome occurring as a result of impaired cardiac function. Understanding the neurohormonal, inflammatory and molecular pathways involved in the pathophysiology of this syndrome has led to the development of effective and widely used pharmacological treatments. Despite this, mortality and hospitalization rates associated with this condition remain high. The natural course of this illness is usually progressive, often leading inexorably to end stage heart failure, for which orthotopic heart transplant is a treatment option but one with limited resource. In the past decade, mechanical circulatory support has emerged as a potential therapy for certain patients with advanced heart failure. This article reviews the published data regarding biomarkers in the setting of mechanical circulatory support, and highlights areas of ongoing work and potential future areas of interest.
No takes yet. Share an insight, caveat, or question.
Simpson et al. (2014) conducted a review in Heart failure. Biomarkers in mechanical circulatory support was evaluated. This article reviews the published data regarding biomarkers in the setting of mechanical circulatory support for advanced heart failure, highlighting areas of ongoing work and future interest.
Synapse has enriched 10 related papers. Consider them for comparative context: